Oramed submitted a new Investigational New Drug application with the U.S. Food and Drug Administration for a sub-study on its oral insulin candidate, ORMD-0801 (Oramed)
Diabetes News Service
Oramed submitted a new Investigational New Drug application with the U.S. Food and Drug Administration for a sub-study on its oral insulin candidate, ORMD-0801 (Oramed)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales